Ocular Therapeutix vs Tango Therapeutics
Tango Therapeutics is the larger business, with $62.4m of revenue in fiscal 2025 against $52.0m for Ocular Therapeutix (1.2 times as much). Tango Therapeutics grew faster (48.3% against -18.5%). Tango Therapeutics kept more of each dollar of sales as profit: a net margin of -162.9% against -511.9%.
| Latest fiscal year | Ocular TherapeutixOCUL, 2025 | Tango TherapeuticsTNGX, 2025 |
|---|---|---|
| Revenue | $52.0m | $62.4m |
| Revenue growth | -18.5% | 48.3% |
| Net income | −$266m | −$102m |
| Operating margin | -519.8% | — |
| Net margin | -511.9% | -162.9% |
| Return on equity | -54.9% | -37.2% |
| Free cash flow | −$217m | −$140m |
| Cash | $737m | $112m |
| Total debt | $71.3m | $0 |
| Debt to equity | 10.9% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 325 | 137 |
| Market value | $1.52bn | $3.95bn |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 1 buys, 29 sales | 0 buys, 25 sales |